21.89

0.65% 0.165

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $21.89, with a volume of 467.70K. It is up +0.65% in the last 24 hours and down -15.85% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Previous Close:

$21.72

Open:

$21.152

24h Volume:

467.70K

Relative Volume:

0.18

Market Cap:

$2.20B

Revenue:

$352.57M

Net Income/Loss:

$-143.01M

P/E Ratio:

-12.09

EPS:

-1.81

Net Cash Flow:

$-153.40M

1W Performance:

+0.97%

1M Performance:

-15.85%

6M Performance:

+22.20%

1Y Performance:

-9.10%

1-Day Range:

$20.80

$22.24

1-Week Range:

$20.76

$24.08

52-Week Range:

$13.53

$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1137)

Industry

Biotechnology (634)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

510

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	21.90	2.20B	352.57M	-143.01M	-153.40M	-1.81
ARGX Argen X Se Adr	917.36	55.90B	3.06B	1.28B	447.35M	19.67
VRTX Vertex Pharmaceuticals Inc	435.55	110.91B	11.74B	3.68B	3.34B	14.19
INSM Insmed Inc	193.48	41.21B	447.02M	-1.18B	-906.14M	-6.1812
ONC Beone Medicines Ltd Adr	376.00	40.48B	4.98B	69.59M	525.67M	0.5197
REGN Regeneron Pharmaceuticals Inc	701.58	72.89B	14.25B	4.58B	3.88B	41.77

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

Nov 16, 2025

Published on: 2025-11-16 06:02:52 - newser.com

Nov 16, 2025

Analyzing drawdowns of Beam Therapeutics Inc. with statistical toolsOptions Play & Safe Capital Investment Plans - newser.com

Nov 16, 2025

Historical volatility pattern of Beam Therapeutics Inc. visualizedJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - newser.com

Nov 16, 2025

How Beam Therapeutics Inc. stock compares to market leaders2025 Market Sentiment & Consistent Income Trade Ideas - newser.com

Nov 16, 2025

Nov 15, 2025

(BEAM) Risk Channels and Responsive Allocation - news.stocktradersdaily.com

Nov 15, 2025

What hedge fund activity signals for Beam Therapeutics Inc. stockJuly 2025 Snapshot & Reliable Intraday Trade Alerts - newser.com

Nov 15, 2025

How buybacks impact Beam Therapeutics Inc. stock value2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com

Nov 15, 2025

Why Beam Therapeutics Inc. stock is favored by pension fundsPortfolio Value Summary & High Conviction Investment Ideas - newser.com

Nov 15, 2025

Nov 14, 2025

Why retail investors favor Beam Therapeutics Inc. stock2025 Analyst Calls & Weekly High Return Forecasts - newser.com

Nov 14, 2025

Beam Therapeutics (BEAM): Exploring Valuation as Clinical Milestones Revitalize Investor Interest - Yahoo Finance

Nov 14, 2025

Will Beam Therapeutics Inc. stock deliver long term returnsPortfolio Growth Summary & Consistent Return Investment Signals - newser.com

Nov 14, 2025

Nov 13, 2025

How to monitor Beam Therapeutics Inc. with trend dashboards2025 Buyback Activity & Weekly Stock Breakout Alerts - newser.com

Nov 13, 2025

Institutional scanner results for Beam Therapeutics Inc.Market Growth Review & Community Consensus Trade Signals - newser.com

Nov 13, 2025

Nov 12, 2025

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - The Globe and Mail

Nov 12, 2025

Nov 10, 2025

Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results - MSN

Nov 10, 2025

Nov 09, 2025

15 Stocks Set to Explode in 2026 - Insider Monkey

Nov 09, 2025

Beam Therapeutics Stock (BEAM) Opinions on Clinical Trial Updates - Quiver Quantitative

Nov 09, 2025

Beam Therapeutics Bets Big On Precision Gene Editing - Finimize

Nov 09, 2025

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent

Nov 09, 2025

Nov 07, 2025